THE LONDON COPD RSV study
The London COPD cohort respiratory syncytial virus (RSV) study
Duration of Study in the UK
3 years, 0 months, 1 days
The aim of this study is to determine the prevalence and consequences of infection of the lung by a respiratory virus called Respiratory Syncytial Virus (RSV). Infection by RSV can cause severe disease in the very young, elderly and in high-risk groups, and may if not irradicated from the lung have long term consequences in COPD.
The research studies will examine whether this virus can be found in sputum or in nasal samples, when patients are stable or when ill with an acute worsening of respiratory symptoms termed an “exacerbations”. Exacerbations occur at about 1-2 per year and are important events as they can cause a number of problems such as hospital admission, worsening lung function and being less able to leave the home.
If the study confirms earlier scientific evidence then it may be worthwhile in the future vaccinating COPD patients against RSV. Vaccines currently for children are under development and could be used in COPD patients.
London - Harrow Research Ethics Committee
Date of REC Opinion
18 Oct 2017
Further Information Favourable Opinion